BioLineRx second quarter net loss decreases to NIS 16.

BioLineRx second quarter net loss decreases to NIS 16.4 million BioLineRx Ltd cialis pas cher http://tadalafil-en-belgique.com . , a biopharmaceutical development company, reported its results for the next quarter ending June 30 today, 2011. Currently, our pipeline includes 13 substances actively being developed, with five in scientific stages. This consists of commencement of the Clearness Phase II/III scientific trial for BL-1020 in Romania, with individual enrollment starting on plan through the second quarter. We are happy with the improvement of the trial so far, and appearance forward to starting affected person enrollment at the trial’s specified sites in India, mentioned Kinneret Savitsky, Ph.D., CEO of BioLineRx. Relating to BL-1040, our collaboration with Ikaria proceeds, and we anticipate commencement of the 1st pivotal medical trial in the next half of 2011.